Skip to main content

Table 3 Evaluation for PAS and association with immunoreactivity for p63, α-SMA, E-cadherin and Ki-67 in groups

From: Versican expression in canine carcinomas in benign mixed tumours: is there an association with clinical pathological factors, invasion and overall survival?

 

Score

Areas

  

In situ

Invasive

  

Group 1

Group 2

Group 1

Group 2

p63

0

0/20

1/21

12/21

13/21

 

1

0/20

3/21

6/21

5/21

 

2

7/20

6/21

3/21

3/21

 

3

13/20

11/21

0/21

0/21

α-SMA

0

1/20

6/21

13/21

14/21

 

1

5/20

5/21

8/21

6/21

 

2

4/20

3/21

0/21

1/21

 

3

10/20

7/21

0/21

0/21

E-cadherin

0

0/24

0/24

17/25

15/24

 

1

3/24

7/24

8/25

9/24

 

2

21/24

17/24

0/25

0/24

Ki-67 (Mean value)

 

5.6 (22)

8.7 (22)

5.62 (22)

12 (22)

  1. Group 1, represented by cases with low versican expression; and Group 2, represented by cases with versican overexpression.
  2. Significant differences at P < 0.0001 between in situ and invasive areas in p63, α-SMA, and e-cadherin using the Wilcoxon Test.
Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us